<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01265069</url>
  </required_header>
  <id_info>
    <org_study_id>201005064M</org_study_id>
    <nct_id>NCT01265069</nct_id>
  </id_info>
  <brief_title>Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy</brief_title>
  <official_title>Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, a 10-day concomitant therapy has been reported to be equally effective and safe to&#xD;
      the 10-day sequential therapy for 1st-line anti-Helicobacter pylori(H. pylori) therapy. To&#xD;
      our knowledge, there has been no report concerning the efficacy of this regimen used as a&#xD;
      rescue therapy.&#xD;
&#xD;
      The aims of this study are:&#xD;
&#xD;
        1. to compare the efficacy of high dose dual therapy and concomitant therapy as rescue&#xD;
           regimen in H. pylori eradication;&#xD;
&#xD;
        2. to compare the patient adherence and adverse effects of these treatment regimens;&#xD;
&#xD;
        3. to investigate factors that may influence H. pylori eradication by these treatment&#xD;
           regimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients, aged 18, having H. pylori-positive chronic gastritis with/without peptic ulcers&#xD;
      will be recruited. All undergo endoscopy with biopsy before treatment. Four to eight weeks&#xD;
      after termination of treatment, H. pylori infection status will be examined by endoscopy with&#xD;
      biopsy or the Carbon 13-urea breath test if the patients refuse the second endoscopy. The&#xD;
      cytochrome P450 (CYP)2C19 genotype of each participant will be analyzed by the polymerase&#xD;
      chain reaction-based restriction fragment length polymorphism (PCR-RFLP) method. A computed&#xD;
      generated random numbers sequence will be blocked into two subgroups, say A and B.&#xD;
&#xD;
      If the patients had received anti-H. pylori therapy previously, they will be invited to enter&#xD;
      the study for evaluating the efficacy of rescue regimens. After giving their written informed&#xD;
      consent, all patients will be labeled with numbers by enrolling order. Each patient will be&#xD;
      randomly allocated to one of two treatment groups which receives medications for 10 to 14&#xD;
      days:&#xD;
&#xD;
      group A - high dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14&#xD;
      days); group B - concomitant therapy (rabeprazole 20 mg + amoxicillin 1000 mg + metronidazole&#xD;
      500 mg + clarithromycin 500 mg, bid for 10 days).&#xD;
&#xD;
      All patients will be asked to complete a questionnaire and to record symptoms and drug&#xD;
      consumption daily in a diary card during the treatment period. Post-treatment, the patients&#xD;
      will be seen at the Outpatient Clinic to investigate patient adherence and adverse effects of&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to compare the efficacy of 10-day concomitant regimen versus high dose dual therapy used as atni-Helicobacter pylori rescue therapy</measure>
    <time_frame>1.5 years</time_frame>
    <description>The eradication rates (efficacy) will be evaluated by intention-to-treat (ITT) and per-protocol (PP) analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to compare the adverse effects and patient adherence of 10-day concomitant regimen versus high dose dual therapy used as atni-Helicobacter pylori rescue therapy</measure>
    <time_frame>1.5 years</time_frame>
    <description>The safety and tolerability will be evaluated by the number of participant with adverse events and patient adherence (by counting unused medication after the treatment and record symptoms in a diary card).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>high dose dual therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A - high dose dual therapy (rabeprazole 20 mg qid, amoxicillin 750 mg qid for 14 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>concomitant therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B - concomitant therapy (rabeprazole 20 mg, amoxicillin 1000 mg, metronidazole 500 mg, clarithromycin 500 mg, bid for 10 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose dual therapy</intervention_name>
    <description>rabeprazole 20mg qid,amoxicillin 750mg qid for 14days</description>
    <arm_group_label>high dose dual therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>concomitant therapy</intervention_name>
    <description>rabeprazole 20 mg,amoxicillin 1000 mg,metronidazole 500 mg,clarithromycin 500 mg, bid for 10 days</description>
    <arm_group_label>concomitant therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients having H. pylori related chronic gastritis with/without peptic ulcers who are&#xD;
             aged greater than 18 years and are willing to received eradication therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or nursing woman&#xD;
&#xD;
          -  serious concomitant illness and malignant tumor of any kind&#xD;
&#xD;
          -  history of hypersensitivity to test drugs&#xD;
&#xD;
          -  serious bleeding during the course of this ulcer&#xD;
&#xD;
          -  previous gastric surgery&#xD;
&#xD;
          -  receiving bismuth salts, proton pump inhibitors, or antibiotics in the previous month.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jyh-Chin Yang, M.D.Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jyh-Chin Yang, M.D.Ph.D</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>65055</phone_ext>
    <email>jcyang47@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10043</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyh-Chin Yang, M.D.Ph.D.</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>65055</phone_ext>
      <email>jcyang47@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>December 10, 2010</study_first_submitted>
  <study_first_submitted_qc>December 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2010</study_first_posted>
  <last_update_submitted>May 31, 2013</last_update_submitted>
  <last_update_submitted_qc>May 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>concomitant therapy</keyword>
  <keyword>high dose dual therapy</keyword>
  <keyword>antibiotic resistance</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

